NCT00074009已完成2 期
A Multicenter, Open-Label, Two-Stage, Phase II Study Of PS-341 (LDP-341, NSC # 681239) In Patients With Unresectable Or Metastatic Gastric Adenocarcinoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 7
研究概览
简要总结
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.
详细描述
OBJECTIVES:
Primary
- Determine the efficacy of bortezomib in patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Secondary
- Determine the toxicity of this drug in these patients.
- Determine possible predictors of response to this drug, using pretreatment tumor immunohistochemistry, in these patients.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
Bortezomib in Treating Patients With Malignant Pleural MesotheliomaMalignant MesotheliomaNCT00513877Cancer Trials Ireland33
已完成
2 期
Bortezomib in Treating Patients With Advanced or Metastatic SarcomaSarcomaNCT00027716Memorial Sloan Kettering Cancer Center
已完成
2 期
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's LymphomaLymphomaNCT00428142NCIC Clinical Trials Group95
已完成
2 期
PAD. ICORG 05-01, V11Multiple Myeloma and Plasma Cell NeoplasmNCT00814541Cancer Trials Ireland53
已完成
1 期
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerOvarian CancerNCT00028912Memorial Sloan Kettering Cancer Center